EyePoint Pharmaceuticals Inc’s recently made public that its 10% Owner Cormorant Asset Management, LP acquired Company’s shares for reported $10.49 million on Apr 18 ’24. In the deal valued at $18.03 per share,581,765 shares were bought. As a result of this transaction, Cormorant Asset Management, LP now holds 7,475,000 shares worth roughly $126.7 million.
Then, Jones David Scott sold 209 shares, generating $5,954 in total proceeds. Upon selling the shares at $28.49, the SVP & Chief Commercial Officer now owns 37,962 shares.
Before that, Paggiarino Dario A. sold 49,325 shares. EyePoint Pharmaceuticals Inc shares valued at $1,265,539 were divested by the Chief Medical Officer at a price of $25.66 per share. As a result of the transaction, Paggiarino Dario A. now holds 36,505 shares, worth roughly $0.62 million.
JP Morgan initiated its EyePoint Pharmaceuticals Inc [EYPT] rating to an Overweight in a research note published on January 22, 2024; the price target was $35. A number of analysts have revised their coverage, including Mizuho’s analysts, who began to cover the stock in early November with a ‘”a Buy”‘ rating. Robert W. Baird began covering EYPT with “an Outperform” recommendation on April 21, 2023. Chardan Capital Markets started covering the stock on July 07, 2022. It rated EYPT as “a Buy”.
Price Performance Review of EYPT
On Monday, EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] saw its stock fall -3.97% to $16.95. Over the last five days, the stock has lost -20.35%. EyePoint Pharmaceuticals Inc shares have fallen nearly -26.66% since the year began. Nevertheless, the stocks have risen 198.42% over the past one year. While a 52-week high of $30.99 was reached on 02/08/24, a 52-week low of $5.32 was recorded on 04/22/24. SMA at 50 days reached $23.62, while 200 days put it at $16.03. A total of 1.39 million shares were traded, compared to the trading of 4.14 million shares in the previous session.
Levels Of Support And Resistance For EYPT Stock
The 24-hour chart illustrates a support level at 16.32, which if violated will result in even more drops to 15.70. On the upside, there is a resistance level at 17.76. A further resistance level may holdings at 18.58. The Relative Strength Index (RSI) on the 14-day chart is 29.05, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.11, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.83%. Stochastics %K at 8.99% indicates the stock is a buying.
The most recent change occurred on March 01, 2021 when Cowen began covering the stock and recommended ‘”an Outperform”‘ rating along with a $25 price target.
